Midlife Serum Cholesterol and Increased Risk of Alzheimer’s and Vascular Dementia Three Decades Later
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Aims: To investigate midlife cholesterol in relation to Alzheimer’s disease (AD) and vascular dementia (VaD) in a large multiethnic cohort of women and men. Methods: The Kaiser Permanente Northern California Medical Group (healthcare delivery organization) formed the database for this study. The 9,844 participants underwent detailed health evaluations during 1964–1973 at ages 40–45 years; they were still members of the health plan in 1994. AD and VaD were ascertained by medical records between 1 January 1994 and 1 June 2007. Cox proportional hazards models – adjusted for age, education, race/ethnic group, sex, midlife diabetes, hypertension, BMI and late-life stroke – were conducted. Results: In total, 469 participants had AD and 127 had VaD. With desirable cholesterol levels (<200 mg/dl) as a reference, hazard ratios (HR) and 95% CI for AD were 1.23 (0.97–1.55) and 1.57 (1.23–2.01) for borderline (200–239 mg/dl) and high cholesterol (≥240 mg/dl), respectively. HR and 95% CI for VaD were 1.50 (1.01–2.23) for borderline and 1.26 (0.82–1.96) for high cholesterol. Further analyses for AD (cholesterol quartiles, 1st quartile reference) indicated that cholesterol levels >220 mg/dl were a significant risk factor: HR were 1.31 (1.01–1.71; 3rd quartile, 221–248 mg/dl) and 1.58 (1.22–2.06; 4th quartile, 249–500 mg/dl). Conclusion: Midlife serum total cholesterol was associated with an increased risk of AD and VaD. Even moderately elevated cholesterol increased dementia risk. Dementia risk factors need to be addressed as early as midlife, before underlying disease(s) or symptoms appear.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Findings in late-life cohorts vary, with some finding higher levels of cholesterol associated with a lower risk356 and others finding a higher risk for VaD.357”
In the citing paper
“there are several controllable risk factors including obesity [156,157], hyperlipidemia [158,159], hypertension [160,161,162,163], type 2 diabetes [164,165,166,167], and sedentary lifestyle [168] that can be addressed in an effort to decrease the risk of developing AD.”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [158]
In the citing paper
“Obesity,71–73 dyslipidemia,74–77 and high BP78,79 are also major contributors to vascular brain health.”
From Defining Optimal Brain Health in Adults: A Presidential Advisory From the American Heart Association/American Stroke Association (2017) · cites this paper as [75]
Citations
Cites
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Hachinski, V., Iadecola, C., Petersen, R. C., Breteler, M. M., Nyenhuis, D. L., Black, S. E., Powers, W. J., DeCarli, C., Merino, J. G., Kalaria, R. N., et al. (2006) · Stroke · doi:10.1161/01.str.0000237236.88823.47 · Cited by 1,722 · cited 1×
“significantly increased the risk of developing VaD 3 decades later. High cholesterol levels (≥240 mg/dl) tended to increase VaD risk as well, but the association did not reach statistical significance. One reason for this could be the small sample size of VaD (127 persons in total, 39 with high cholesterol).VaD repres…”
BackgroundKrieger, N. (1992) · American Journal of Public Health · doi:10.2105/ajph.82.5.703 · Cited by 1,654 · cited 1×
“The present study investigates further the cholesterol-dementia relationship by focusing on the 2 main dementia subtypes, AD and vascular dementia (VaD), in a larger Kaiser Permanente cohort with updated follow-up information. We also examined the full range of cholesterol values (not just high cholesterol, >240 mg/dl…”
BackgroundMidlife cardiovascular risk factors and risk of dementia in late life
Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C., & Yaffe, K. (2005) · Neurology · doi:10.1212/01.wnl.0000149519.47454.f2 · Cited by 1,238 · cited 1×
“High midlife cholesterol has previously been shown to be a risk factor for dementia in the multiethnic cohort of women and men from the Kaiser Permanente Medical Care Program of Northern California [”
BackgroundSelf-citationKivipelto, M., Ngandu, T., Laatikainen, T., Winblad, B., Soininen, H., & Tuomilehto, J. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70537-3 · Cited by 1,126 · cited 1×
“Although our cohort does not include persons with mixed dementia as recognized by ICD-9 CM, the concomitant presence of neurodegenerative and vascular pathologies in a portion of the sample cannot be excluded. Clinical Significance and ConclusionsPhysicians tend to confine AD and VaD to geriatric age borders, and addr…”
ResultSelf-citationSerum Total Cholesterol, Apolipoprotein E {FC12}e4 Allele, and Alzheimer’s Disease
Notkola, I.-L., Sulkava, R., Pekkanen, J., Erkinjuntti, T., Ehnholm, C., Kivinen, P., Tuomilehto, J., & Nissinen, A. (1998) · Neuroepidemiology · doi:10.1159/000026149 · Cited by 669
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Iivonen, S., Mannermaa, A., Tuomilehto, J., Nissinen, A., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-3-200208060-00006 · Cited by 645
Self-citationIribarren, C., Sidney, S., Sternfeld, B., & Browner, W. S. (2000) · JAMA · doi:10.1001/jama.283.21.2810 · Cited by 482
Kalmijn, S., Foley, D., White, L., Burchfiel, C. M., Curb, J. D., Petrovitch, H., Ross, G. W., Havlik, R. J., & Launer, L. J. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.10.2255 · Cited by 417 · cited 1×
“but no association was observed in the Honolulu Asia Aging Study (HAAS) or Framingham study [”
BackgroundCrossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain
BJÖRKHEM, I. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01725.x · Cited by 381
Cited by
Items 301–400 of 553
Prevalence and Ascertainment of Dementia Cases in the Malmö Diet and Cancer Study
Nägga, K., Bränsvik, V., Stomrud, E., Melander, O., Nilsson, P. M., Gustavsson, A., & Hansson, O. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220003 · Cited by 14
Liu, C., Guo, X., Wang, B., Meng, T., Li, C., Zhou, Y., & Fu, J. (2024) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000539482 · Cited by 12
“Lipid metabolism disorder is one of the common metabolic abnormalities in diabetic patients [12].”
Lifestyle and Alzheimer’s Disease
Bartolotti, N., & Lazarov, O. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802851-3.00007-3 · Cited by 18
Piniewski, B., Codagnone, C., & Osimo, D. (2011) · Joint Research Centre (European Commission) · doi:10.2791/562 · Cited by 17
“Similarly has been noted that early (in mid life) cholesterol changes and cardiovascular risk can be followed decades later by the onset of dementia [43, 44].”
BackgroundAlzheimer’s: A Progressive Brain Disease: Causes, Symptoms, and Prevention
Amin, F., Shamsi, A., Asghar, M. N., Khaki, P. S. S., Khan, M. S., Tabrez, S. S. M., Zaidi, S. K., Khan, W., & Bano, B. (2019) · Springer eBooks · doi:10.1007/978-981-13-9636-6_2 · Cited by 15
Safari, S., Mirazi, N., Ahmadi, N., Asadbegi, M., Nourian, A., Ghaderi, S., Rashno, M., & Komaki, A. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03225-x · Cited by 12
Kaur, N., Sarkar, B., Mittal, S., Dhiman, M., Taglialatela, G., Perez‐Polo, R. J., & Mantha, A. K. (2014) · Springer eBooks · doi:10.1007/978-81-322-2035-0_13 · Cited by 14
Association between plasma biomarkers, CDK5 polymorphism and the risk of Alzheimer’s disease
Czapski, G. A., Maruszak, A., Styczyńska, M., Żekanowski, C., Safranow, K., & Strosznajder, J. B. (2012) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2012-1911 · Cited by 14
“The increased cholesterol level, which is a risk factor for Alzheimer’s disease (Solomon et al. 2009), may enhance CDK5 activity, leading to deregulation of phosphorylation processes, including hyperphosphorylation of Microtubule-associated protein (MAP) tau.”
BackgroundResultChen, J., Cui, G.-H., Jiang, G., Xu, R.-F., Tang, H., Wang, G., Chen, S., & Cheng, Q. (2014) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317514534758 · Cited by 13
“Many large epidemiological studies had showed that midlife serum TC was associated with an increased risk of later cognitive impairment.(38,39) The inconsistent results may be explained in part by the different timing of the cholesterol measurement in relationship with the age of study patients and the clinical onset…”
BackgroundBruce, D. G., Davis, W. A., & Davis, T. M. E. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.12.009 · Cited by 12
Correlation study of Framingham risk score and vascular dementia
Li, S.-S., Zheng, J., Mei, B., Wang, H.-Y., Zheng, M., & Zheng, K. (2017) · Medicine · doi:10.1097/md.0000000000008387 · Cited by 13
“96).([28]) Thus, high cholesterol level was considered as one of the risk factors of VaD.”
BackgroundGenetic Interaction with Plasma Lipids on Alzheimer’s Disease in the Framingham Heart Study
Peloso, G. M., Beiser, A., DeStefano, A. L., & Seshadri, S. S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180751 · Cited by 12
Cerebrovascular Disease and Cognitive Outcome in Patients with Cardiac Disease
Johansen, M. C., & Gottesman, R. F. (2021) · Seminars in Neurology · doi:10.1055/s-0041-1726330 · Cited by 16
Hasan, Z. M., Rolle-McFarland, D., Liu, Y., Zhou, J., Mostafaei, F., Li, Y., Fan, Q., Zhou, Y., Zheng, W., Nie, L. H., et al. (2020) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2020.126469 · Cited by 14
“However, this is challenging, as development of AD occurs over many years or decades [18,19], yet standard quantitative methods to assess Al exposure reflect much shorter time periods.”
BackgroundSelf-citationLipids in the Treatment of Neurodegenerative Diseases
Lange, K. W. (2020) · Wiley eBooks · doi:10.1002/047167849x.bio118 · Cited by 12
Microglia contribute to cognitive decline in hypercholesterolemic LDLr −/− mice
Rodrigues, M. S., do Nascimento, N. B., Farias, H. R., Schons, T., Machado, A. G., Medeiros, E. B., Mesquita, A., Bast, R. K., Budni, J., Engblom, D., et al. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15952 · Cited by 14
“Epidemiological and experimental evidence indicates that hypercholesterolemia, especially FH, negatively affects cognition, favoring the development of neuropathologies (Kivipelto et al., 2001 ; Solomon et al., 2009 ; Ullrich et al., 2010 ).”
Establishment of experimental models for Alzheimer's disease research
Li, Y. (2013) · International Journal of Neuroscience · doi:10.3109/00207454.2013.804821 · Cited by 12
“Excessive intake of high cholesterol diet easily leads to hypercholesterolemia, a risk factor for AD and vascular dementia [28].”
BackgroundNormal aging and cognition: The unacknowledged contribution of cerebrovascular risk factors
Morra, L. F., Zade, D. D., McGlinchey, R. E., & Milberg, W. (2012) · Aging Neuropsychology and Cognition · doi:10.1080/13825585.2012.693905 · Cited by 14
“In the Cardiovascular Risk Factors Aging and Dementia study, elevated mid-life cholesterol was found to increase the risk for cognitive impairment ( Solomon, Kivipelto, Wolozin, Zhou, & Whitmer, 2009 ).”
BackgroundRotonen, S., AUVINEN, J. P., Bloigu, A. H., Härkönen, P. K., Jokelainen, J. J., Timonen, M., & Keinanen-Kiukaanniemi, S. M. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109045 · Cited by 11
Fresnais, D., Humble, M. B., Bejerot, S., Meehan, A. D., & Fure, B. (2021) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000518295 · Cited by 13
Atherosclerosis, biomarkers of atherosclerosis and Alzheimer's disease
Fiolaki, A., Tsamis, K. I., Milionis, H. J., Kyritsis, A. P., Kosmidou, M. S., & Giannopoulos, S. (2013) · International Journal of Neuroscience · doi:10.3109/00207454.2013.821988 · Cited by 12
“The association of midlife hypercholesterolemia and AD was also confirmed by other studies [17,47].”
ResultRogne, S., Vangberg, T. R., Eldevik, P., Wikran, G., Mathiesen, E. B., & Schirmer, H. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000350408 · Cited by 11
CETP inhibitor evacetrapib enters mouse brain tissue
Phénix, J., Côté, J., Dieme, D., Recinto, S. J., Oestereich, F., Efrem, S., Haddad, S., Bouchard, M., & Munter, L. M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1171937 · Cited by 11
“Interestingly, higher levels of plasma cholesterol and low-density lipoprotein cholesterol (LDL-C) were also associated with an increased risk of developing Alzheimer’s disease (Whitmer et al., 2005; Solomon et al., 2009; Liu et al., 2020).”
BackgroundXie, G., Jiang, G., Huang, L., Sun, S., Wan, Y., Li, F., Wu, B., Zhang, Y., Li, X., Xiong, B., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18060790 · Cited by 13
“Additionally, midlife hypercholesterolemia was found to be a substantial risk factor for the progression of AD in a 30-year longitudinal cohort study [10], which has informed subsequent research on the possible use of statin medications for AD prevention and treatment [11].”
A study of mild cognitive impairment in veterans: role of hypertension and other confounding factors
Bai, J., Wei, P., Zhao, N., Xiao, Y., Yang, C., Zhong, J., Cai, Y., Li, Y., Zhu, Q., Cao, X., et al. (2016) · Aging Neuropsychology and Cognition · doi:10.1080/13825585.2016.1161000 · Cited by 11
Wang, Y., Wang, P., Zhang, Q., Zhang, H., Li, Z., Liu, X., Kaur, L., & Kumar, M. (2020) · Pharmacognosy Magazine · doi:10.4103/pm.pm_438_19 · Cited by 13
Development of AD-Like Pathology in Skeletal Muscle
Chen, X., Miller, N. M., Afghah, Z., & Geiger, J. D. (2019) · Journal of Parkinson’s Disease and Alzheimer’s Disease · doi:10.13188/2376-922x.1000028 · Cited by 14
“Second, elevated levels of plasma LDL cholesterol, independent of APOE genotypes, are linked robustly to the pathogenesis of AD [109-115].”
BackgroundWang, K., & Zhang, W. (2021) · Synapse · doi:10.1002/syn.22196 · Cited by 11
“Thus, serum cholesterol levels may facilitate as a predictor, which cannot be explained by the amyloid hypothesis (Gottesman et al., 2017; Schilling et al., 2017; Solomon et al., 2009).”
BackgroundHa, J., Kwon, G. E., Son, Y., Jang, S. A., Cho, S. Y., Park, S. J., Kim, H. J., Lee, J., Lee, J., Seo, D., et al. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13706 · Cited by 9
“5,43,44 A recent study further demonstrated a signi fi cant correlation between brain/CSF 7 β -OHC levels (with 7-ketocholesterol) and Braak staging.”
El-Sayed, N. S., Khalil, N. A., Saleh, S. R., Aly, R. G. M., & Basta, M. (2024) · Journal of Molecular Neuroscience · doi:10.1007/s12031-024-02232-4 · Cited by 9
“Furthermore, a disturbed lipid profile is linked to an increased risk of AD (Solomon et al. 2009).”
Alzheimer's Disease and Vascular Dementia, Connecting and Differentiating Features
Hurła, M., Banaszek, N., Kozubski, W. P., & Dorszewska, J. (2024) · Current Alzheimer Research · doi:10.2174/0115672050319219240711103459 · Cited by 10
Intermittent Metabolic Switching and Vascular Cognitive Impairment
Rajeev, V., Tabassum, N. I., Fann, D. Y., Chen, C., Lai, M. K. P., & Arumugam, T. V. (2024) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes24010 · Cited by 11
“90 IF has demonstrated the ability to improve lipid profiles in various animal and human studies, increasing serum HDL levels and other lipids, thereby reducing the risk of cardiovascular diseases.”
BackgroundDietary interventions for maintaining cognitive function in cognitively healthy people in mid life
Harrison, S. L., Birdi, R., Smart, C., Brittain, K., Rutjes, A. W., Siervo, M., & Stephan, B. C. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011911 · Cited by 9
Association between Cholesterol Exposure and Neuropathological Findings: The ACT Study
Bettcher, B. M., Ard, M. C., Reed, B., Benitez, A. M., Simmons, A. L., Larson, E. B., Sonnen, J. A., Montine, T. J., Li, G., Keene, C. D., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161224 · Cited by 9
Yu, G.-X., Initiative, A. D. N., Zhang, T., Hou, X., Ou, Y., Hu, H., Wang, Z.-T., Guo, Y., Xu, W., Tan, L., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201117 · Cited by 10
“Accumulating evidence has indicated a vascular contribution to AD [2–4], with multiple vascular risk factors associated with an increased risk of AD, including hypertension [5], diabetes [6], smoking [7], and hypercholesterolemia [8].”
BackgroundThe Role of High-Density Lipoprotein in Lowering Risk of Dementia in the Elderly: A Review
., A., Avula, S. N., Joseph, K.-L.-T. N., Onuchukwu, C. V., Thondamala, V., Shrivastava, S., Namburi, A. R., & Mohammed, L. (2022) · Cureus · doi:10.7759/cureus.24374 · Cited by 11
“Maximized serum cholesterol in mid-adult life increases the risk of dementia in older age [4].”
BackgroundPeriyasamy, S., Sathya, M., Chennakesavan, K., Kandasamy, M., Sellathamby, S., Jayavelu, T., Jayachandran, K. S., & Anusuyadevi, M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170272 · Cited by 11
“Recent identification has been extensively recognized that the effect of serum TC on dementia risk that occurs in midlife but not late-life, which may be different for cardiovascular risk factor profile compared to dementia and AD [49, 50].”
de Paula, G. C., de Oliveira, J., Engel, D. F., Lopes, S. C., Moreira, E. L. G., Figueiredo, C. P., Prediger, R. D., & Bem, A. F. D. (2020) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1704472 · Cited by 9
“cognitive impairment (MCI) [2] and Alzheimer’s disease [4].”
BackgroundAffective Symptoms in Early-Onset Dementia
Podell, K., & Torres, K. (2010) · Neurologic Clinics · doi:10.1016/j.ncl.2010.10.009 · Cited by 12
Brain cortical cholesterol metabolism is highly affected by human APP overexpression in mice
Löffler, T., Schweinzer, C., Flunkert, S., Sántha, M., Windisch, M., Steyrer, E., & Hutter‐Paier, B. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2016.03.004 · Cited by 9
Low-Density Lipoprotein Particle Size Subfractions and Cerebral Amyloidosis
Lee, S., Parekh, T., King, S. M., Reed, B., Chui, H. C., Krauss, R. M., & Yassine, H. N. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181252 · Cited by 10
“Epidemiological studies have found that high cholesterol levels are correlated with increased AD dementia risk [15, 16].”
Risk- and protective factors for memory plasticity in aging
Bråthen, A. C. S., de Lange, A. G., Fjell, A. M., & Walhovd, K. B. (2020) · Aging Neuropsychology and Cognition · doi:10.1080/13825585.2020.1727834 · Cited by 12
“effects of cholesterol on cognitive abilities (Anstey, Ashby-Mitchell, & Peters, 2016; Mielke et al., 2005a; Solomon et al., 2009).”
BackgroundAssociations Between High-Density Lipoprotein Cholesterol Efflux and Brain Grey Matter Volume
Giacona, J. M., Wang, J., Zhang, R., Kelley, B. J., Hajjar, I. M., Thomas, B. P., Yu, F. F., de Lemos, J. A., Rohatgi, A. K., & Vongpatanasin, W. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13206218 · Cited by 8
“Several epidemiological studies have demonstrated associations of plasma lipids during early and midlife with the development of cognitive decline and dementia in late life [1–4].”
BackgroundInfluence of cardiovascular risk factors on pre-mild cognitive decline at middle and old age
Koberskaya, N. N., Yakhno, N. N., Гридин, В. Н., & Smirnov, D. S. (2021) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2021-1-13-17 · Cited by 9
Spinedi, M., Clark, C., Zullo, L., Kerksiek, A., Pistis, G., Castelao, E., von Gunten, A., Preisig, M., Lütjohann, D., & Popp, J. (2024) · iScience · doi:10.1016/j.isci.2024.109013 · Cited by 8
“40,41 Furthermore,inpatientswithAlzheimer’sdiseasehigherlevelsoftotalcholesterolwererelatedtocorticalamyloid-betadepositionandaccel-erated cognitivedeterioration.”
Ratio of apoB/LDL: a potential clinical index for vascular cognitive impairment
Qian, C., & Tan, F. (2016) · BMC Neurology · doi:10.1186/s12883-016-0766-1 · Cited by 8
“Furthermore, studies have suggested that cardiovascular risks contribute to VD, cognitive impairment and AD, and hyperlipidemia is one of the atherogenic factors among those cardiovascular risks [1, 16, 17].”
BackgroundSzoeke, C. E. I., Goodwill, A. M., Gorelik, A., Dennerstein, L., Caeyenberghs, K., Simpson, S., Hill, E., & Campbell, S. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180815 · Cited by 9
Association of Cardiovascular Health and Cognition
Kulshreshtha, A., Saini, J., German, T., & Alonso, Á. (2019) · Current Epidemiology Reports · doi:10.1007/s40471-019-00210-8 · Cited by 8
Blood Pressure and Statin Effects on Cognition: a Review
Yang, M., & Williamson, J. D. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0973-4 · Cited by 9
Diabetes and cognitive dysfunction
Kim, B., Sims‐Robinson, C., Sakowski, S. A., & Feldman, E. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00027-7 · Cited by 8
Apolipoprotein E ε-4 as a genetic determinant of Alzheimer’s disease heterogeneity
Kotze, M. J., Brand, T., Pretorius, J., van Rensburg, S. J., & Luckhoff, H. K. (2015) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s41721 · Cited by 15
“33 These conflicting findings may be explained by variation in the timing of cholesterol measurement with regard to age and the course of the underlying disease process.”
Anderson, A., Díaz‐Santos, M., Frei, S., Dang, B. H., Kaur, P., Lyden, P. D., Buxton, R. B., Douglas, P. K., Bilder, R. M., Esfandiari, M., et al. (2020) · Brain Structure and Function · doi:10.1007/s00429-020-02083-w · Cited by 9
Jeong, S. H., Chung, S. J., Yoo, H. S., Jung, J. H., Baik, J. S., Sohn, Y. H., & Lee, P. H. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01326-2 · Cited by 7
“Elevated cholesterol levels are associated with an increased risk of cognitive impairment and dementia, including Alzheimer’s disease (AD) and vascular dementia [5, 6], whereas the other studies showed contradictory results [7–9].”
ResultHan, S., Byun, M. S., Yi, D., Jung, J., Kong, N., Chang, Y. Y., Keum, M., Jung, G. J., Lee, J.-Y., Lee, Y. S., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.131 · Cited by 8
Scilletta, S., Miano, N., Marco, M. D., Musmeci, M., Carasi, S., Capuccio, S., Pistritto, C., Ippolito, C., Tiralongo, M., Ricci, A., et al. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106511 · Cited by 9
Alzheimer disease prevention: New optimism
Filley, C. M. (2015) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000108 · Cited by 7
“Statin drugs are widely prescribed for hyperlipidemia, and could plausibly lower AD risk by addressing this midlife risk factor while cognition is normal.(13,14) RCTs of statins for prevention of AD have thus far been disappointing, but investigation of the possibility that statins may help lower AD risk continues.”
BackgroundMachado, A. E., de Sousa, G., Mancini, G., Faria, M. S., Bem, A. F. D., & Moreira, E. L. G. (2018) · Neuroreport · doi:10.1097/wnr.0000000000001091 · Cited by 7
Alzheimers's disease: Epidemiological characteristics and its prevention
Grujičić, J., & Nikolić, A. (2021) · Zdravstvena zastita · doi:10.5937/zdravzast50-32931 · Cited by 8
The Janus-like Association between Proton Pump Inhibitors and Dementia
Papazoglou, A., Arshaad, M. I., Henseler, C., Daubner, J., Broich, K., Haenisch, B., & Weiergräber, M. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210929144740 · Cited by 8
Dietary interventions for maintaining cognitive function in cognitively healthy people in late life
Siervo, M., Lara, J., Munro, A., Tang, E. Y. H., Rutjes, A. W., & Stephan, B. C. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011910 · Cited by 7
An Integrative Overview of Non-Amyloid and Non-Tau Pathologies in Alzheimer’s Disease
Menta, B. W., & Swerdlow, R. H. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2603-y · Cited by 7
Factors Associated with Cognitive Decline in Transient Ischemic Attack Patients
Sivakumar, L., Camicioli, R. M., & Butcher, K. (2014) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100017248 · Cited by 10
Pollen, D. A., Baker, S. P., Hinerfeld, D. A., Swearer, J. M., Evans, B. A., Evans, J. E., Caselli, R. J., Rogaeva, E. A., George‐Hyslop, P. S., & Moonis, M. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt55 · Cited by 8
“It is also well established that mid-life serum total cholesterol levels are associated with an increased risk of both AD and vascular dementia [48].”
BackgroundPhysical activity and cognition in the elderly
Clifford, A. (2012) · Loughborough University Institutional Repository (Loughborough University) · Cited by 8
Huang, Y., Huang, W., Ma, X., Zhao, G., Kang, J., Li, H., Li, J., Sheng, S., & Qian, F. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1431421 · Cited by 7
Shang, Y., Torrandell‐Haro, G., Vitali, F., Brinton, R. D., & (ADNI), T. A. D. N. I. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70074 · Cited by 9
Cholesterol Levels, Hormone Replacement Therapy, and Incident Dementia among Older Adult Women
Chiu, H.-Y., Chang, H.-T., Chan, P., & Chiu, P. (2023) · Nutrients · doi:10.3390/nu15204481 · Cited by 7
“…have suggested that low cholesterol levels may be associated with an increased risk of dementia, others have found no significant association or have even suggested that high cholesterol levels or elevated levels of LDL-C, often referred to as “bad cholesterol”, may be a greater risk factor [14–18].”
BackgroundAssociations between human blood metabolome and vascular dementia
Jia, Y., Guo, D., Liu, Y., Sun, L., Chang, X., He, Y., Shi, M., Chen, G., Zhang, Y., Li, H., et al. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111150 · Cited by 7
Shen, H., Xiong, Y., Liang, Y., Liu, Z., Guo, L., Qin, Y., He, J., & Lin, F. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s506570 · Cited by 6
History of hypertensive disorders of pregnancy and risk of Alzheimer’s disease and vascular dementia
Kaur, S., Darden, C. J., Adegbola, G. M., & Warrington, J. P. (2025) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2025.101198 · Cited by 6
“Studies have shown that midlife serum total cholesterol, even moderately elevated, was associated with an increased risk of VaD and AD (Solomon et al., 2009).”
Dental X-ray exposure and Alzheimer’s disease: A hypothetical etiological association
Rodgers, C. C. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.03.016 · Cited by 10
“Researchers who compared cholesterol levels of nearly 10,000 men and women in their mid-40s between 1964 and 1973 with their medical records 30 years later found that high cholesterol levels were a good predictor of who would develop AD [84].”
BackgroundChen, X., Wagener, J. F., Ghribi, O., & Geiger, J. D. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00129 · Cited by 6
“…Diet Increases Accumulation of Cholesterol in Endolysosomes and Disturbs Endolysosome Structure and Function Skeletal muscle has a very low capacity to synthesize cholesterol (Spady and Dietschy, 1983) and it meets its cholesterol needs mainly by taking up circulating lipoproteins.”
BackgroundInfluentialAshraf, G. M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.78252 · Cited by 9
Exercise as a Way of Capitalizing on Neuroplasticity in Late Adulthood
Erickson, K. I., Oberlin, L. E., Gujral, S., Leckie, R. L., Weinstein, A. M., Hodzic, J. C., Dabbagh, A., Whitmoyer, P., & Wollam, M. E. (2014) · Topics in Geriatric Rehabilitation · doi:10.1097/tgr.0000000000000008 · Cited by 11
Maintaining Cognitive Health in Elderly Women
Clifford, A., Yesufu-Udechuku, A., Edwards, L., Bandelow, S., & Hogervorst, E. (2009) · Aging Health · doi:10.2217/ahe.09.65 · Cited by 11
Yu, G., Ou, Y.-N., Bi, Y., Ma, Y., Hu, H., Wang, Z.-T., Hou, X., Xu, W., Tan, L., & Yu, J.-T. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.55 · Cited by 7
“CSF Aβ42, t-tau, and p-tau levels were measured by the ELISA kit (Innotest β-AMYLOID (1-42), hTAU-Ag, and PHOSPHO-TAU (181p); Fujirebio, Ghent, Belgium) on the microplate reader (Thermo ScientificTM MultiskanTM MK3).”
BackgroundMethodMetabolic Syndrome and Dementia
Lee, A. Y. (2011) · Journal of the Korean Neurological Association · Cited by 7
Gosselet, F. (2011) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000103e · Cited by 6
“Cholesterol was also identified as dietary risk factor in humans; since elevated serum cholesterol is a risk factor for developing AD and amount of Aβ peptide in the brain correlates with serum levels of LDL and total cholesterol [8,9].”
BackgroundAmyloid beta accumulation in HIV-1 infected brain: the role of altered cholesterol homeostasis.
Chen, X., Liang, H., & Geiger, J. D. (2014) · PubMed · Cited by 6
Ciesielski, T. H., Tosto, G., Durodoye, R. O., Rajabli, F., Akinyemi, R., Byrd, G. S., Bush, W. S., Kunkle, B. W., Reitz, C., Vance, J. M., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01059-3 · Cited by 8
The longitudinal association between dyslipidemia and cognitive trajectory
Pink, A., Krell‐Roesch, J., Syrjanen, J. A., Vassilaki, M. E., Fields, J. A., Iglseder, B., Aigner, E. S., Kremers, W. K., Jack, C. R., Racette, S. B., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251385255 · Cited by 6
“7,8 Similarly, investigators from the Washington Heights – Inwood Columbia Aging Project reported a weak association between higher non-HDL and LDL cholesterol, as well as lower HDL cholesterol levels with the risk of vascular dementia.”
Saini, S., Choudhary, M., & Garg, A. (2021) · Clinical Phytoscience · doi:10.1186/s40816-021-00300-5 · Cited by 9
“Epidemiological studies suggested that high peripheral cholesterol pools increases vulnerability to AD [29, 30] and the countries with high calorie diet shows higher propensity to AD [31].”
BackgroundFerreira, N. V., Bittencourt, M. S., Generoso, G., Gonçalves, N. G., Barreto, S. M., Giatti, L., Santos, R. D., Lotufo, P. A., Benseñor, I. M., & Suemoto, C. K. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119159 · Cited by 5
Kim, H., Park, J., Kim, Y. S., & Park, J. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5458 · Cited by 5
“Even moderately elevated cholesterol level in midlife increases the risk of dementia.(40) The Honolulu-Asia Aging Study (HAAS) reported no correlation between midlife serum total cholesterol level and risk of AD, even though a cluster of cardiovascular metabolic risk factors at midlife increased the risk of dementia.”
BackgroundCan brain impermeable BACE1 inhibitors serve as anti-CAA medicine?
Li, J., Huang, L., Liu, F., Tang, B., & Yan, X. (2017) · BMC Neurology · doi:10.1186/s12883-017-0942-y · Cited by 5
Dominko, K., Đikić, D., & Hecimovic, S. K. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2018.1511027 · Cited by 7
Nilsson, N., Picard, C., Labonté, A., Köbe, T., Meyer, P., Villeneuve, S., Auld, D. S., Poirier, J., & Initiative, A. D. N. (2021) · Genes · doi:10.3390/genes12111805 · Cited by 6
Mobile Application for Monitoring and Preventing Cognitive Decline Through Lifestyle Intervention
Angelis, I., Alvanou, A. G., Avgoustis, N., Vergis, S., Zervopoulos, A., Malakopoulou, M., Bezas, K., Nikiforos, M. N., Papamichail, A., Stylidou, A., et al. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-78775-2_11 · Cited by 5
Cardiovascular risk factors for cognitive deficiency and options for correction
Koberskaya, N. N. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-2-35-43 · Cited by 5
Comorbidity of Dementia: A Cross-Sectional Study of PUMCH Dementia Cohort
Shang, L., Dong, L., Huang, X., Chu, S., Jin, W., Bao, J., Wang, T., Mao, C., & Gao, J. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231025 · Cited by 7
“In addition, several studies reported an association between an elevated serum cholesterol level and an increased risk of AD [33].”
Shebini, S. M. E., Abdel-Moat, M., Kazem, Y. I., Ahmed, N. H., Fouad, S., Mohamed, M. S., Hussein, A. M. S., Hanna, L. M., & Tapozada, S. T. (2017) · Journal of Biological Sciences · doi:10.3923/jbs.2017.202.212 · Cited by 5
Liu, W., Wu, Y., Bai, L., Ni, J., Tu, J., Liu, J., Deng, Q., Ning, X., & Wang, J. (2018) · Neuroepidemiology · doi:10.1159/000490496 · Cited by 6
Multi‐time‐point data preparation robustly reveals MCI and dementia risk factors
Kaur, D., Bucholc, M., Finn, D. P., Todd, S., Wong‐Lin, K., & McClean, P. L. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12116 · Cited by 8
Mu, N., Xu, S., Chang, Q., Rao, D. P., Chen, J., & Ma, C. (2013) · PubMed · Cited by 6
The contribution of N-terminally modified amyloid beta to the etiology of Alzheimer's disease
Wittnam, J. L. (2012) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-3182 · Cited by 6
Lipid trajectories improve risk models for Alzheimer’s disease and mild cognitive impairment
Chase, B. A., Frigerio, R., Yucus, C. J., Patel, S. V., Maraganore, D. M., Sanders, A. R., Duan, J., & Markopoulou, K. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100714 · Cited by 5
Rossi, C., Distaso, M., Raggi, F., Kusmic, C., Faita, F., & Solini, A. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1289750 · Cited by 4
“In the last decade, several epidemiological studies have linked hypercholesterolemia and high-fat diet consumption to cognitive function decline and dementias (1–3).”
BackgroundBarberger‐Gateau, P., Samieri, C., & Cunnane, S. C. (2015) · OCL · doi:10.1051/ocl/2015022 · Cited by 4
“In particular, high blood cholesterol at midlife has been associated with increased risk of late-life cognitive decline and dementia (Solomon et al., 2009).”
Xie, T., Akbar, S., Stathopoulou, M. G., Oster, T., Masson, C., Yen, F. T., & Visvikis‐Siest, S. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.04.013 · Cited by 8
Ledo, A., Rocha, B. S., & Laranjinha, J. A. N. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-11488-6_10 · Cited by 5
Metadata
- Authors
- Solomon, A., Kivipelto, M., Wolozin, B., Zhou, J., & Whitmer, R. A.
- Affiliations
- University of Eastern Finland (FI)
- Boston University (US)
- Kaiser Permanente (US)
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2009
- Volume
- 28
- Issue
- 1
- Pages
- 75-80
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- PMC
- PMC2814023
- OpenAlex
- W2134458253
- Cited by
- 557
- References
- 22
- Citations by year
- 2026: 22 · 2025: 25 · 2024: 36 · 2023: 25 · 2022: 31 · 2021: 42 · 2020: 31 · 2019: 34 · 2018: 37 · 2017: 32 · 2016: 39 · 2015: 27 · 2014: 41 · 2013: 39 · 2012: 42
- FWCI
- 19.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Dementia and Geriatric Cognitive Disorders (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Kaiser Permanente
- National Institute of Diabetes and Digestive and Kidney Diseases (K01DK066308, DK066308)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, vascular dementia, dementia risk factors, total cholesterol, hypercholesterolemia, multi-ethnic cohort, men and women
- MeSH terms
- Adult, Aged, Alzheimer Disease, Cholesterol, Data Interpretation, Statistical, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Socioeconomic Factors, Dementia, Vascular, Cohort Studies, Proportional Hazards Models, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.